Insurances & Business

Genentech, Biogen Say Rituxan Fails in Lupus Study

Investment | Sources: bnet.com

Similar/Related/News:

• Genentech, Biogen shares dip on late-stage drug failure (AP)
Shares of Genentech Inc. and Biogen Idec Inc. fell Tuesday after the biotechnology companies reported a failure of their drug Rituxan to prompt a resp...
• The Systemic Lupus Erythematosus Patient Population in the Seven Major Markets Is Estimated to Be 430,000 In 2008 as the Market is Set to Enter Era of Biologic Therapies (Business Wire)
DUBLIN, Ireland----Research and Markets has announced the addition of Stakeholder Opinions: Systemic Lupus Erythematosus - Market Set to Enter Era of ...
• Web 2.0 fails to produce cash
Many members of the Web 2.0 generation of internet companies have so far produced little in the way of revenue, despite bringing about some significan...
• Hungary crisis deepens as yields soar
Hungary’s currency plunges to fresh lows against euro after the country fails to attract enough investors at a bond auction to reach its target...
• Millionaires’ Appetite For Stocks Rising: Study
NEW YORK (Reuters) - Millionaires view the U.S. economy as "very weak," but sense a resumption of growth in early 2009 and expect to buy stocks an...
• Study Finds Public Health Programs Require Less Per-Person Spending Than Private Plans
"Public and Private Insurance: Stacking Up the Costs," Health Affairs: The Web exclusive study -- by Leighton Ku, a professor at the George Washington...
• Corporate Political Ties Impact Share Prices: Study
NEW YORK (Reuters) - Companies with a board member who has ties to a winning political party enjoy a significant bounce in their share price follo...
• U.S. Housing Rebound to Be Prolonged: Harvard Study
NEW YORK (Reuters) - Record foreclosures and limited access to credit will make it harder than usual to rebound from this U.S. housing market slum...